HOUSTON INNOVATORS PODCAST EPISODE 48

Greater Houston Partnership researcher identifies the city's top tech specialties

Josh Pherigo at GHP used data to look into what tech specialties are thriving in Houston — and what niches have shown promising growth. Photo via LinkedIn

When you look at Houston's venture capital investment patterns, what do they tell you? To Josh Pherigo, research director of data analytics at the Greater Houston Partnership, it paints a picture of what tech and startup niches are thriving.

Based on PitchBook data, Pherigo put together an analysis of what industries within Houston are attracting the most investments. The study came out of the fact that Houston's hold on oil and gas is going to shift as the industry goes through the energy transition. Since O&G is such a crucial part of Houston's economy, the city will have to see a rise in new industries to remain competitive with its economy.

"The idea was to look at the innovation ecosystem and see what the technologies are that are doing well here at at attracting VC funding," Pherigo says on the Houston Innovators Podcast. "And by seeing how well certain technologies are doing, we'll be able to see if these are some areas that have some natural competitive advantages in Houston's economy that we can then use to spur growth in the next few decades — and even just out of the recession we're in right now."

The report found that life science and oil and gas currently attract the most VC investments in Houston, but Pherigo found potential in a few other industries like B2B payments technology — Houston-based fintech startup, HighRadius recently raised $125 million.

The study, which also compared Houston to Austin and Dallas, found that there was a cleantech war emerging between Austin and Houston. While Houston's ecosystem has a greater presence of cleantech startups, Austin cleantech is still bringing in more VC investments. However, in Houston, between new corporate incubators and Greentown Labs entering Houston, the city is creating a lot of infrastructure for this industry.

"It's going to be interesting over the next few years to see how Houston can position itself as the leader in Texas for this, because they are going to have a lot of competition from Austin," Pherigo says.

Pherigo goes into more detail about what he found interesting in the report, and even dives into what the data shows for the future of Houston's tech specialties in the episode of the podcast. You can listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News